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Abstract
The release of adrenocorticotropin (ACTH) from the corticotrophs is
controlled principally by vasopressin and corticotropin-releasing hor-
mone (CRH). Oxytocin may augment the release of ACTH under
certain conditions, whereas atrial natriuretic peptide acts as a cortico-
tropin release-inhibiting factor to inhibit ACTH release by direct
action on the pituitary. Glucocorticoids act on their receptors within
the hypothalamus and anterior pituitary gland to suppress the release
of vasopressin and CRH and the release of ACTH in response to these
neuropeptides. CRH neurons in the paraventricular nucleus also project
to the cerebral cortex and subcortical regions and to the locus ceruleus
(LC) in the brain stem. Cortical influences via the limbic system and
possibly the LC augment CRH release during emotional stress, whereas
peripheral input by pain and other sensory impulses to the LC causes
stimulation of the noradrenergic neurons located there that project
their axons to the CRH neurons stimulating them by a-adrenergic
receptors. A muscarinic cholinergic receptor is interposed between the
a-receptors and nitric oxidergic interneurons which release nitric
oxide that activates CRH release by activation of cyclic guanosine
monophosphate, cyclooxygenase, lipoxygenase and epoxygenase. Va-
sopressin release during stress may be similarly mediated. Vaso-
pressin augments the release of CRH from the hypothalamus and also
augments the action of CRH on the pituitary. CRH exerts a positive
ultrashort loop feedback to stimulate its own release during stress,
possibly by stimulating the LC noradrenergic neurons whose axons
project to the paraventricular nucleus to augment the release of CRH.
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Introduction
Dramatic progress has been made in pep-
tide research over the last 45 years, and we
now know the specific hypothalamic pep-
tides that control the release of various pitu-
itary hormones. In the mid-1940s it was
recognized that neural stimuli could evoke
release of hormones from the anterior pitui-
tary. Examples included coitus-induced ovu-
lation in birds, ferrets, cats, and other mam-
mals, suckling-induced prolactin (PRL) re-
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lease, and stress-induced release of adrenal
corticotropic hormone (ACTH). One of the
most important discoveries in the field was
that of the hypophyseal portal system of
veins by Popa and Fielding in 1933. These
originate from capillaries in the median emi-
nence (ME), drain blood down the hypophy-
seal stalk, and supply the sinusoids of the
anterior lobe of the pituitary gland. Although
blood flow was initially thought to be up-
ward in these vessels, Houssay and his col-
leagues observed downward flow in the liv-
ing toad in 1935. This observation was con-
firmed in the living rat by Green and Harris
in 1947. It is apparent then that the primary
flow is downward from the ME to the pitui-
tary; however, there is evidence that upward
flow may indeed occur under certain condi-
tions.
In the meantime, it became apparent that
there was little if any functional innervation
to the anterior lobe, prompting a number of
workers to suggest that hypothalamic con-
trol over the pituitary might be mediated via
neurohumoral agents released into the capil-
laries of the hypophyseal portal system that
would pass down the pituitary stalk and stimu-
late the release of particular pituitary hor-
mones from the cells in the gland specialized
to produce each hormone. Indeed, deficits in
pituitary hormone secretion followed lesions
placed in various hypothalamic loci, and
conversely, electrical stimulation of these
same regions was shown to evoke release of
gonadotropins and ACTH. That the portal
system was a crucial link between brain and
pituitary was suggested by the experiments
of Harris and his collaborators who showed
that following stalk section the portal vessels
frequently regenerated, and a return of nor-
mal pituitary function accompanied this re-
generation. On the other hand, a plate placed
between the cut ends of the stalk to block
such regeneration caused a permanent im-
pairment in pituitary function. In other ex-
periments it was shown that if the pituitary
was removed from its capsule and then im-
mediately transplanted under the ME, so that
it was vascularized by the portal vessels,
pituitary function returned to normal. A cor-
ollary of this experiment was carried out by
Nikovitch-Winer and Everett who showed
that pituitary grafts under the kidney capsule
did not sustain normal pituitary function but
later regrafting under the ME returned func-
tion to normal (for reviews, see Refs. 1 and
2).
Corticotropin-releasing factors
The next logical step was to make ex-
tracts of the ME and to evaluate their effects
on pituitary hormone secretion. Because of
the early development of sensitive assays for
determining ACTH release, attention first
focused on the ability of such extracts to
evoke ACTH release. Because of the ready
availability of partially purified extracts of
the posterior pituitary, which were used in
the preparation of commercial vasopressin
(Pitressin) and oxytocin (Pitocin), these ex-
tracts were tested in early experiments. To
make extracts of the stalk ME required labo-
rious collection of the tissue at the slaughter-
house. The initial choice of posterior pitui-
tary extracts for testing was unfortunate but
led to the discovery of the ACTH-releasing
activity of vasopressin (3). Just after this,
vasopressin was synthesized by Du Vigneaud
and colleagues (see Ref. 4), and the synthetic
material was shown to be active in vivo to
release ACTH in animals with ME lesions
that blocked the ubiquitous release of ACTH
from stress. It was reported that a substance
different from vasopressin could be isolated
from posterior pituitary extracts that also
released ACTH; this substance was named
corticotropin-releasing factor (CRF) (5,6).
Early claims for a CRF other than vaso-
pressin in posterior pituitary extracts have
not been confirmed (7,8). Guillemin and
Schally even claimed to have partial struc-
tures of ß CRF and a I and II CRF. Again,
these claims have not been confirmed (8). At
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this point in time, it is clear that there is such
a factor in posterior lobe extracts; however,
it is a minor contaminant and the major
ACTH-releasing activity of such extracts is
accounted for by vasopressin (8,9).
It was only when attention was turned to
extracts of the stalk ME that it became clear
that indeed there was a separate corticotro-
pin-releasing hormone (CRH) different from
vasopressin (9). This material was purified
and separated from vasopressin (10), but its
isolation and determination of structure
proved difficult. In fact, although CRH was
the first releasing factor to be discovered, it
was one of the last whose structure was
elucidated, probably because it was a much
larger polypeptide. This feat was finally ac-
complished by Vale and Rivier and their
colleagues in 1981 (11). CRH turned out to
be a 41-amino acid peptide, completely dis-
tinct from the octapeptide vasopressin, and
with no disulfide group in the molecule.
It is now clear that vasopressin and CRH
share physiological roles as CRFs. The vaso-
pressin neuronal system has cell bodies pri-
marily in the supraoptic nucleus (SON) but
also in the paraventricular nucleus (PVN)
and axons that project primarily to the neural
lobe; however, some of these axons, particu-
larly those from the PVN, terminate in the
external layer of the ME in juxtaposition to
portal vessels. High concentrations of vaso-
pressin and CRH are found in the portal
vessels, and both peptides release ACTH in
concentrations similar to those found in por-
tal blood (12). There is a defect, albeit small,
in ACTH secretion in animals with heredi-
tary diabetes insipidus that lack vasopressin
secretion (13). Vasopressin can potentiate
the response to CRH at the pituitary level as
revealed by both in vivo (14) and in vitro
experiments (15). The peptide is also active
in the hypothalamus to potentiate the release
of CRH (16). Antisera directed against vaso-
pressin injected into the third ventricle pro-
duce a partial block in ACTH secretion, and
a partial block has also been achieved with
vasopressin antagonists (17). There are va-
sopressin type II receptors similar to those in
the vascular system on anterior pituitary
corticotrophs that act to increase intracellu-
lar calcium in these cells (12), inducing a
release of ACTH. On the other hand, CRH
acts on CRH type I receptors on the cortico-
troph to activate adenylyl cyclase, leading to
an increase in cyclic adenosine monophos-
phate (cAMP) that induces ACTH release
(12).
An early candidate for CRF was epineph-
rine; however, its direct CRF activity ap-
peared to be ruled out by the ability of ME
lesions to block the response to epinephrine.
This early concept is now reemerging in
view of the ability of epinephrine to evoke
ACTH release both in vivo and in vitro by an
action on ß-receptors which have been dis-
covered in the gland. Epinephrine is released
during stress and could activate ACTH se-
cretion either by the increased concentra-
tions in the circulation or by its release into
portal blood, which would provide much
higher concentrations of the catecholamine.
In fact, high concentrations of epinephrine
have recently been reported in portal blood.
From all of this, it is apparent that there is no
single CRF. Instead there is a constellation
of agents that can release ACTH and may
play physiological roles in evoking the stress-
induced release of the peptide (12).
The perikarya of CRH and vasopressin
neurons are located predominately in parvo-
cellular neurons of the SON and PVN. The
preponderance of vasopressin neurons is in
the SON and of CRH neurons in the PVN.
The axons project to the ME where the pre-
ponderance of vasopressin axons continues
into the neural lobe to release the peptide
there. The preponderance of CRF neurons
terminates in the external layer of the ME
and only a few project to the neural lobe.
Early studies indicated that lesions in the
ME that induce severe diabetes insipidus
block ACTH secretion, presumably because
they block these axons of vasopressin and
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CRH neurons reaching the ME from both the
PVN and SON (3). Lesions of the PVN did
not block the stress response when studied 2
to 3 weeks later, but were associated with
adrenal atrophy (3); however, later studies
showed that lesions of the PVN were effec-
tive to block ACTH secretion when tested
only 5 days after lesions (18). These experi-
ments support the concept that both PVN
and SON are involved in ACTH secretion by
release of CRH and vasopressin, the former
into the hypophyseal portal vessels in the
ME and the latter also into the short portal
vessels in the neural lobe. These supply 1/3
of the blood to the anterior lobe and prob-
ably play an important role in control of
anterior lobe function through release of
hypothalamic factors into these vessels, in
particular, vasopressin in the case of ACTH
secretion, a fact that has been largely ig-
nored.
Some of the CRH neurons in the PVN
projecting to the ME also contain vasopressin,
and the relative abundance of vasopressin is
increased in the adrenalectomized animal.
Therefore, vasopressin appears particularly
to be important in the increase in ACTH
secretion that occurs following adrenalec-
tomy. Indeed, vasopressin appears to be more
important than CRH in control of ACTH
secretion in sheep. The relative importance
of vasopressin and CRH appears to vary
depending on the stress imposed and the
details of this relationship have yet to be
fully determined. As pointed out above, the
two synergize to stimulate ACTH release
(see Ref. 17 for a review).
Oxytocin, another peptide released from
the magnocellular neurons in the PVN and
SON, is also released from axonal terminals
in juxtaposition to the portal vessels. It is
present in high concentrations in portal blood
and also has the capacity to potentiate the
response to CRH at the pituitary level. Since
oxytocin is released in stress as well as vaso-
pressin and CRF, it may play a small role in
the stress-induced release of ACTH (19).
Similarly, angiotensin II neurons within
the hypothalamus that project to the ME may
play a small augmenting role since the pep-
tide is present in portal blood and has an
intrinsic capacity to stimulate the cortico-
trophs (20). There are also receptors for this
peptide on pituitary cells. Angiotensin II is
an important hormone that is released in
states of reduction of the circulating blood
volume and that is associated with ACTH
release (20). Atrial natriuretic peptide (ANP)
has opposite effects; namely it is released in
states of volume expansion and causes di-
uresis and natriuresis (20,21). ANP also acts
centrally to inhibit vasopressin secretion and
has now been clearly shown to have an
inhibitory action to suppress CRH release
intrahypothalamically and inhibit the pitui-
tarys response to CRH, leading some to call
it a corticotropin release-inhibiting factor
(20,21).
Many of these actions of angiotensin II
and ANP are physiologically significant as
revealed by injection of antisera against these
peptides into the third cerebral ventricle
(19,22). ANP is also synthesized in the ante-
rior pituitary gland and there are receptors in
the gland to mediate its action (22).
The principal ANP receptor is guanylyl
cyclase. It causes conversion of guanosine
triphosphate into cyclic guanosine mono-
phosphate (cGMP) that induces a decrease
in intracellular free calcium (Ca2+) in the
corticotroph, thereby inhibiting ACTH se-
cretion (Antunes-Rodrigues J, Yu WH and
McCann SM, unpublished results). Interest-
ingly, neural nitric oxide (NO) synthase
(nNOS) is also localized in pituitary cells.
When activated by transmitters it produces
an increase in intracellular free Ca2+ in the
pituitary cells containing the enzyme that
generates NO by conversion of arginine in
the presence of oxygen and various cofac-
tors. This NO diffuses to the corticotroph
and activates guanylyl cyclase, leading to
increased cGMP formation that decreases
intracellular free Ca2+, thereby inhibiting
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ACTH secretion. Thus, agents that generate
NO in the pituitary, such as cytokines would
be expected to suppress rather than stimulate
ACTH secretion. Indeed, experiments have
indicated that NO will suppress ACTH se-
cretion by direct action on the gland and it
has been shown that increased NO will in-
hibit the stimulatory effect of vasopressin on
ACTH secretion (23).
Control of vasopressin CRH and
ACTH secretion by negative
feedback of cortical steroids
It was shown by Ingle in 1936 that there
was a negative feedback action of adrenal
cortical steroids to suppress adrenal cortical
hypertrophy following unilateral adrenalec-
tomy. This action is mediated by a direct
suppression of the response of the cortico-
troph to vasopressin (24) and CRH (25). The
mechanism of this has yet to be fully eluci-
dated. Furthermore, there is also an action of
glucocorticoids on the hypothalamus to sup-
press the release not only of vasopressin
but also of CRH. Following adrenalec-
tomy the release of vasopressin and CRH
is increased and vasopressin appears to be
colocalized with CRH in more neurons
than in the intact animal. The actions at
both the pituitary and hypothalamic levels
are mediated by glucocorticoid receptors
which have been localized in the pituitary
gland and also in the region of the CRH
neurons in the PVN (26).
Distribution and control of CRH
neurons by intra- and extra-
hypothalamic neuronal systems
Not only do vasopressinergic and
CRHergic neurons project to the ME and
neural lobe of the pituitary gland, but also
they project to cortical and subcortical struc-
tures and caudally to the brain stem (26).
Therefore, it is not surprising that input from
the cerebral cortex via limbic system areas,
as occurs for example in emotional arousal,
can activate CRH release followed by ACTH
and cortical hormone secretion (27,28). The
mechanism of this pathway is not known;
however, this may be by activation of locus
ceruleus (LC) neurons and other brain stem
noradrenergic (NAergic) neurons that are
known to project NAergic axons to the PVN.
Indeed, lesions of the LC will temporarily
completely block the release of ACTH in-
duced by ether anesthesia in the rat (29).
Indeed, the LC might be characterized as
a head ganglion of the sympathoadrenal sys-
tem, so that it is activated by stressful stimuli
in the periphery and by afferent input by pain
and other sensory modalities (29). It also can
be stimulated by activation from the cerebral
cortex via the limbic system (30). The result
is not only activation of CRH release by
projections to the CRH neurons in the PVN,
but also activation of the peripheral sympa-
thoadrenomedullary system by producing a
massive discharge of sympathetic terminals
into the vascular blood system and also on
the adrenal medulla producing what Cannon
called the flight or fight response. With the
realization that the hypothalamic pituitary
adrenal (HPA) axis also participated in this
response, interest in the activation of the
peripheral sympathoadrenomedullary sys-
tem has waned; however, evidence that
has accrued in recent years indicates that
there is a direct sympathetic innervation of
the adrenal cortex and that adrenomedullary
rests are present in the adrenal cortex. Fur-
thermore, catecholamines can stimulate re-
lease of adrenocortical steroids from the
ACTH-primed adrenal cortex. Indeed, in
chronic stress the continued activation of the
sympathoadrenomedullary system sensitizes
the cortex to the action of CRH and can even
activate the cortex directly. Therefore, con-
tinued activation of the sympathoadreno-
medullary system can contribute to the in-
creased adrenal cortical steroid production
in chronic stress, even though the elevated
plasma cortical hormone levels will inhibit
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the response of the pituitary to CRH and also
diminish the release of CRH into the hypo-
physeal portal vessels (31).
Ultrashort loop positive feedback of
CRH to stimulate its own secretion
Microinjection of tiny amounts of CRH
into the third ventricle that had no effect on
plasma ACTH resulted in a rapid augmenta-
tion of the ACTH release in response to ether
stress (32). Therefore, it appears that an
ultrashort loop positive feedback of CRH
exists to augment its own secretion that op-
erates only during stress. The site of action
of CRH to augment its own release has not
been determined. However, this may be me-
diated by the stimulatory effect of the LC on
CRH release since the intraventricularly in-
jected CRH would reach the LC and might
stimulate it to send NAergic input into the
CRH neurons, thereby stimulating additional
CRH release. Further experiments need to
be performed to determine if this is the mech-
anism by which CRH augments its own re-
lease. The positive feedback of CRH to aug-
ment its own release appears to be physi-
ologically significant since antiserum against
CRH injected into the third ventricle aug-
mented ACTH release during stress (33).
Intrahypothalamic action of CRH to
inhibit growth hormone (GH) and
luteinizing hormone (LH) release
Not only does CRH augment its own
release by an ultrashort loop positive feed-
back, but it also can inhibit GH and LH
release following its intraventricular injec-
tion (33-36). It is known that in the rat stress
inhibits GH and LH release (33,37) and this
intrahypothalamic action of CRH may play
an important physiological role in inhibiting
the release of these hormones, thereby in-
ducing the profile of release of these hor-
mones which occurs in stress. In essence in
the rat all stresses, if severe enough, will
inhibit GH and LH release and this probably
has a protective value by turning off repro-
ductive function and growth to mobilize all
of the resources of the body to combat the
imposed stress.
Role of the hypothalamic pituitary
adrenal system in stress
Stress may be defined as any stimulus
that distorts homeostasis in the organism.
Therefore, stress can be physical as in the
case of excessive heat or cold, trauma, surgi-
cal operations or infection or it can be emo-
tional and psychological. Selye, who coined
the term, even talked about the stress of life
itself. It is the stresses of life that contribute
to degenerative disease and old age (38).
Stress can affect every organ system in
the body, but the principal mediators of the
response to stress are the sympathetic ner-
vous system and the HPA axis. Various hy-
pothalamic releasing and inhibiting hormones
are released from their axon terminals in the
ME into the capillaries of the hypophyseal
portal veins that transport them to the ante-
rior lobe of the pituitary gland. There they
stimulate or inhibit the release of the various
pituitary hormones that act either directly on
body tissues or on their target glands, which
in turn release hormones that act on various
tissues of the body. Examples of the latter
are ACTH, follicle-stimulating hormone
(FSH), LH and thyroid-stimulating hormone
(TSH), and of the former, are PRL and GH.
Physiological stress is presumably medi-
ated by anxiety recognized in the cerebral
cortex that stimulates limbic system struc-
tures and probably the LC and other brain
stem NAergic neurons that activate CRH
release by NAergic axons which terminate
in the vicinity of CRH neurons in the PVN.
Vasopressin release is also stimulated; how-
ever, this pathway has not been elucidated.
In the case of physical stress, such as pain,
cold, heat or trauma, there is afferent input
by sensory neurons to the brain stem again
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activating the LC that then triggers CRH and
probably vasopressin secretion.
The role of NO in the stress response
In the dozen years since the discovery of
NO in the body and the enzymes forming it,
it has become evident that NO plays a pivotal
role in the function of every organ system of
the body. In this brief review, we will first
examine the role of NO under physiological
conditions and then indicate how this role is
affected by stress. In this connection, most
attention has focused on the role of NO in the
induction of the responses to infection. Little
attention has been given so far to its role in
psychological and other types of stress.
Nearly all types of stress elicit a stereo-
typed pattern of pituitary hormone secretion
in humans which consists of a rapid increase
in ACTH, PRL and GH secretion (in the rat
GH secretion is inhibited) and inhibition of
the secretion of LH, TSH and to a lesser
extent FSH. The pattern is caused primarily
by alterations in the secretion of hypotha-
lamic releasing and inhibiting hormones.
The role of the hypothalamic
pituitary adrenal system in infection
The hypothalamic-pituitary response to
infection can be mimicked by the injection
of bacterial lipopolysaccharide (LPS) iv or
ip. This induces an identical pattern of pitu-
itary hormone secretion as that seen in infec-
tion. There is a very rapid increase in plasma
ACTH and PRL within a few minutes fol-
lowing iv injection of LPS. The response is
dose-related and is accompanied by a rapid
inhibition of LH and TSH but not FSH secre-
tion. GH secretion is stimulated in humans
but suppressed in the rat (37).
Recent work indicates that central ner-
vous system infection is a powerful inducer
of cytokine production in glia and neurons of
the brain, which causes induction of induc-
ible NOS (iNOS) and production of poten-
tially toxic quantities of NO. Following iv
injection of an intermediate dose of LPS,
there was an induction of IL (interleukin)-1a
immunoreactive neurons in the preoptic-hy-
pothalamic region (37). These cells were
shown to be neurons by the fact that double
staining revealed the presence of neuron
specific enolase. The neurons were found in
saline-injected control animals suggesting
that they are normally present, but they in-
creased in number by a factor of 2 within 2 h
following injection of LPS. They are located
in a region which also contains the thermo-
sensitive neurons. They may be the neurons
that are stimulated to induce fever following
injection of LPS. They have short axons that
did not clearly project to the areas containing
the various hypothalamic releasing and in-
hibiting hormones, but they could also be
involved in the stimulation or inhibition of
their release, which occurs following infec-
tion.
This study led to further research which
demonstrated that ip injection of a moderate
dose of LPS induced IL-1ß and iNOS mRNA
in the brain, anterior pituitary and pineal
glands. The results were very exciting since
an induction of IL-1ß and iNOS mRNA oc-
curred with the same time-course as found in
the periphery following injection of LPS,
namely, clear induction of IL-1ß followed
by iNOS mRNA within 2 h reaching a peak
in 4-6 h, followed by a decline to near basal
levels at the next measurement by 24 h after
the injection. The induction of both mRNAs
occurred in the meninges, the choroid plexus,
the circumventricular organs, such as the
subfornical organ and ME, in the ependymal
cells lining the ventricular system, and very
suprisingly in parvocellular neurons of the
PVN and arcuate nucleus (AN), areas of
particular interest since they contain the hy-
pothalamic releasing and inhibiting hormone
producing neurons and also other neuro-
transmitters controlled by NO (39).
The greatest induction occurred in the
anterior lobe of the pituitary, where the iNOS
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mRNA was increased at 2 h by a factor of 45
and in the pineal where the activity was
increased by a factor of 7 at 6 h, whereas the
increase in the PVN was 5-fold. At 6 h, the
medial basal hypothalamus was found to
have an increased content of NOS measured
in vitro and the collected cerebrospinal fluid
(CSF) had increased concentrations of the
NO metabolite, nitrate. These results indi-
cate that the increase in iNOS mRNA was
followed by de novo synthesis of iNOS that
liberated NO into the tissue and also into the
CSF. Presumably, LPS was bound to its
receptors in the circumventricular organs
and in the choroid plexus. These receptors,
as in macrophages, activated DNA-directed
IL-1ß mRNA synthesis which, in turn, caused
the synthesis of IL-1ß. IL-1ß then activated
iNOS mRNA and synthesis (39).
How can neurons in the AN and PVN be
activated since they are inside the blood
brain barrier? In the case of the AN, the
neurons may have axons that project to the
ME. These neurons may have LPS receptors
on their cell surface which then induce IL-ß
mRNA and IL-1ß synthesis. IL-1ß then in-
duces iNOS mRNA followed by NO synthe-
sis. Alternatively, LPS acting on its recep-
tors may simultaneously induce IL-ß mRNA
and iNOS mRNA.
Active transport mechanisms for IL-1 and
other cytokines (40), and perhaps LPS, are
present in the choroid plexus. The cells of
the choroid plexus, on the basis of our re-
sults, must have LPS receptors on them. LPS
then stimulates IL-1ß and iNOS mRNA fol-
lowed by synthesis of IL-1ß and iNOS in the
choroid plexus. LPS and IL-1ß are then trans-
ported into the CSF. LPS is carried by CSF
flow to the third ventricle, where it either
crosses the ependyma or acts on terminals of
PVN neurons in the ependyma to induce IL-
1ß and iNOS mRNA.
This massive delayed increased NO pro-
duction should further increase the effects of
NO to maintain the pattern of hypothalamic
hormone secretion already induced by LPS.
Unfortunately, the effects of inhibitors of
NOS on these later stages in the response to
LPS or infection have not yet been studied.
Interestingly enough, in studies on LHRH
release induced by NO, it has been shown
that increasing concentrations of NO provid-
ed by release from sodium nitroprusside pro-
duce a bell-shaped dose-response curve in
terms of LHRH release with values reaching
a peak and then declining as the concentra-
tion of NO increases (41). Therefore, the
massive increase in NO produced by iNOS
several hours after injection of LPS might
actually reduce the effects of NO on releas-
ing hormone discharge below the peaks
achieved earlier.
In addition to inducing production of
proinflammatory cytokines such as IL-1, IL-
2, IL-6, and TNFa, LPS also induces pro-
duction of anti-inflammatory cytokines, such
as IL-10 and IL-13 and IL-1 receptor antago-
nist in the brain, pituitary and pineal gland
(42). In the periphery these inhibit the in-
flammatory response induced by the proin-
flammatory cytokines. Limited studies indi-
cate that these anti-inflammatory cytokines
antagonize the actions of the proinflamma-
tory cytokines in the brain as well as the
hypothalamic-pituitary response to infection
(42).
The initial response to LPS is mediated
by the constitutive nNOS present in the brain.
There is no participation of the NO synthe-
sized by iNOS in this initial response. In-
deed, the initial response must be due to
action on receptors for LPS on the endings of
vagal afferents and also in areas where the
blood brain barrier is not present, such as the
choroid plexus, ME, organum vasculosum
lamina terminalis, area postrema, and other
circumventricular organs. Input to the hypo-
thalamus from LPS by vagal afferents occurs
at least in part by activation of the LC that
sends NAergic axons to the hypothalamus to
activate CRH release. LPS alters the release
of the various hypophysiotropic hormones
increasing release of CRH and vasopressin,
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GHRH and somatostatin, particularly in the
rat, which overpowers the effect on the re-
lease of GHRH (41). LPS decreases release
of the PRL-inhibiting hormone, dopamine,
LHRH, TRH, but not FSHRF (37). All of
these pathways involve participation of nNOS
as described above (43).
CRH release from hypothalami incubated
in vitro is controlled by muscarinic cholin-
ergic receptors since it can be blocked by
atropine (44,45). The acetylcholine-produc-
ing interneurons in the hypothalamus re-
lease acetylcholine that stimulates a musca-
rinic-type receptor which in turn stimulates
CRH release from the CRH neurons. nNOS
has been located in neurons in the PVN of
the hypothalamus. Stimulated CRH release
can be blocked by NG-monomethyl-L-argi-
nine, a competitive inhibitor of all forms of
NOS. Consequently, CRH release from the
neurons in the PVN is stimulated by cholin-
ergic neurons that synapse on these NOergic
neurons to activate NOS. NOS synthesizes
NO that diffuses into the CRH neurons and
activates CRH release by activating cyclo-
oxygenase I (COX I), leading to the genera-
tion of prostaglandin E2 from arachidonate
(AA). Prostaglandin E2 activates CRH via
activation of adenylyl cyclase and genera-
tion of cAMP. cAMP activates protein ki-
nase A that induces exocytosis of CRH se-
cretory granules into the hypophyseal portal
vessels that then activates ACTH release
from the corticotrophs of the anterior pitui-
tary gland. NO activates not only COX but
also lipoxygenase (LOX) that also plays a
role in the activation of CRH release (46).
NO also activates guanylyl cyclase that con-
verts guanosine triphosphate into cGMP.
cGMP is postulated to increase intracellular
Ca2+ required to activate phospholipase A2
that converts membrane phospholipids into
AA, the substrate for COX and LOX, per-
mitting generation of prostaglandins and
leucotrienes, respectively (44,45).
Activation of CRH release can be blocked
by the synthetic glucocorticoid dexametha-
sone (46) and also by blockers of the three
pathways of AA metabolism, such as clotri-
mazole that blocks epoxygenase, which in
turn converts AA into epoxides; by in-
domethacin that inhibits COX and by 5811-
eicisotrionoic acid that blocks LOX. Thus,
CRH release is activated by the AA cascade
(44). Alpha melanotropic-stimulating hor-
mone also inhibits CRH release (46).
Cyclosporin inhibits CRH release as well
(47), probably by inhibiting calcineurin.
Calcineurin dephosphorylates NOS render-
ing it inactive.
Of the many proinflammatory cytokines,
it has been shown that IL-1a or ß, TNFa, IL-
6 and IL-2 can stimulate ACTH release from
the anterior pituitary in vitro and in vivo
(43). The principal action probably occurs,
at least acutely, on the release of CRH and
vasopressin from the hypothalamus but also
there are clear effects at the pituitary level.
There have been few studies on the mechan-
ism of this direct pituitary action of cyto-
kines, however, several cytokines such as
IL-6 have been found to be produced in
pituitaries and there is also nNOS present in
the gland as indicated earlier. There are indi-
cations that NO participates in inhibiting the
response of ACTH to vasopressin (23).
Whether it plays a role in the stimulatory
action of the various proinflammatory cyto-
kines on ACTH secretion has not yet been
studied.
In our studies LPS itself had no acute
effect on ACTH release from hemianterior
pituitaries in vitro (37). However, LPS in-
duces cytokine production in the pituitary.
Cytokine production would be increased
in a few hours and undoubtedly would modify
the responses of the pituitary to the contin-
ued altered secretion of releasing and inhib-
iting hormones.
In addition to the proinflammatory cyto-
kines which we have discussed extensively,
it is now clear that there are a number of anti-
inflammatory cytokines, the first one to be
discovered being the IL-1 receptor antago-
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nist, but IL-10 and IL-13 also play this role
as indicated above. These are also induced in
the brain by LPS and may play roles at
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